// App-Quantinova.ai

SAT0410 : EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS BASED ON CONCOMITANT CONVENTIONAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (CDMARD) USE: RESULTS FROM SPIRIT-P1 AND SPIRIT-P2

Researchers

Presenter

  • L. C. Coates

Principal Investigators

  • A. Kronbergs

  • A. T. Sprabery

  • S. Y. Park

  • B. Combe

  • A. Deodhar

Medical Centers

  • University of Oxford, Oxford, United Kingdom

  • Eli Lilly and Company, Indianapolis, United States of America

  • CHU Montpellier, Montpellier University, Montpellier, France

  • Oregon Health & Science University, Portland, United States of America

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Hydroxychloroquine

  • Sulfasalazine

  • Methotrexate

  • Cyclosporine A

  • HWA-486

  • LY2439821

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01695239

  • NCT02349295

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved